-
Brazil's 'action agenda' at COP30 takes shape
-
Trump threatens $1 billion action as BBC apologises for edit error
-
Sinner dominates injury-hit Auger-Aliassime in ATP Finals opener
-
Trump hails Syria's 'tough' ex-jihadist president after historic talks
-
Syria's ex-jihadist president meets Trump for historic talks
-
Top US court hears case of Rastafarian whose hair was cut in prison
-
US mediator Kushner and Netanyahu discuss phase two of Gaza truce
-
End to US government shutdown in sight as Democrats quarrel
-
Trump threatens air traffic controllers over shutdown absences
-
US to remove warnings from menopause hormone therapy
-
UK water firm says 'highly likely' behind plastic pellet pollution incident
-
Syria's ex-jihadist president holds historic Trump talks
-
End to record-long US government shutdown in sight
-
France's ex-leader Sarkozy says after jail release 'truth will prevail'
-
Atalanta sack coach Juric after poor start to season
-
Trump threatens $1 billion action as BBC apologises for speech edit
-
Gattuso wants 'maximum commitment' as Italy's World Cup bid on the line
-
Indian capital car blast kills at least eight
-
Deadly measles surge sees Canada lose eradicated status
-
Brazil's Lula urges 'defeat' of climate deniers as COP30 opens
-
Strangled by jihadist blockade, Malians flee their desert town
-
US Supreme Court declines to hear case challenging same-sex marriage
-
'Fired-up' Fritz sees off Musetti in ATP Finals
-
Injured Courtois set to miss Belgium World Cup qualifiers
-
Bulatov, pillar of Russian contemporary art scene, dies at 92
-
Fritz sees off Musetti in ATP Finals
-
US strikes on alleged drug boats kill six more people
-
Sarkozy released from jail 'nightmare' pending appeal trial
-
COP30 has a mascot: the fiery-haired guardian of Brazil's forest
-
The Sudanese who told the world what happened in El-Fasher
-
Three things we learned from the Sao Paulo Grand Prix
-
ASC acquire majority share in Atletico Madrid
-
Ferrari boss tells Hamilton, Leclerc to drive, not talk
-
Bank of England seeks to 'build trust' in stablecoins
-
China suspends 'special port fees' on US vessels for one year
-
French court frees ex-president Sarkozy from jail pending appeal
-
No link between paracetamol and autism, major review finds
-
Typhoon Fung-wong floods Philippine towns, leaves 5 dead in its wake
-
France's Sarkozy says prison a 'nightmare' as prosecutors seek his release
-
Guinness maker Diageo picks new CEO after US tariffs cloud
-
China suspends 'special port fees' on US vessels
-
US senators take major step toward ending record shutdown
-
Typhoon Fung-wong leaves flooded Philippine towns in its wake
-
From Club Med to Beverly Hills: Assinie, the Ivorian Riviera
-
The 'ordinary' Arnie? Glen Powell reboots 'The Running Man'
-
Typhoon exposes centuries-old shipwreck off Vietnam port
-
French court to decide if ex-president Sarkozy can leave jail
-
China lifts sanctions on US units of South Korea ship giant Hanwha
-
Japan death row inmate's sister still fighting, even after release
-
Taylor sparks Colts to Berlin win as Pats streak hits seven
US FDA says Pfizer Covid vaccine effective in kids under five
The US Food and Drug Administration (FDA) has said the Pfizer Covid vaccine is safe and effective in children under five, ahead of a meeting to weigh its authorization later this week.
Children under five are the only age group not yet eligible for vaccination in the United States and most countries, a pressing need since rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age," the FDA said in a document posted on its website Sunday.
The agency has called a meeting of experts on June 15 to decide whether to recommend the Pfizer vaccine, given as three shots to children aged six months through four years, as well as the Moderna vaccine, given as two shots to children aged six months through five years.
Pfizer's first two shots are given three weeks apart, then the third is given eight weeks after the second. They are all dosed at three micrograms, as opposed to 30 micrograms the company gives older ages.
Both Pfizer and Moderna had previously posted their results, but the FDA then had to review the data in detail and carry out its own evaluation. It posted a favorable analysis about Moderna on Friday.
Its comments towards Pfizer also appear favorable, based on the levels of infection-blocking antibodies it evoked in trial participants, and a similar side-effect profile to higher age groups. The trial population was around 4,500 children.
A preliminary estimate placed vaccine efficacy at 80.3 percent, but the FDA noted this was based on very few positive cases -- just 10, as opposed to the 21 sought for a more accurate figure.
There are nearly 20 million US children aged four years and under, or six percent of the population. If, as expected, the FDA-appointed experts recommend the two shots, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
J.Oliveira--AMWN